Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Associations of Serum 25-Hydroxyvitamin D Concentrations and Lipid Profiles Across Adiposity Status Among Children and Adolescents Aged 9-17 Years: A Cross-Sectional Study in Guangzhou, China.

Nutrients·2026
Same author

Discovery of Ligands for the TNFR1 Extracellular Domain Using Fragment-Based Drug Discovery.

ChemMedChem·2026
Same author

FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma.

ACS applied materials & interfaces·2026
Same author

Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.

Signal transduction and targeted therapy·2026
Same author

Associations of Dietary Patterns and Dietary Index with Iron Deficiency Across Different Stages Among Children Aged 9-17 Years in Guangzhou, China: A Cross-Sectional Study.

Nutrients·2026
Same author

A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis.

European journal of medicinal chemistry·2026

相关实验视频

Updated: Jul 13, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K

在开发针对Keap1的非共价小分子方面取得了进展.

Marilia Barreca1, Yuting Qin2, Marie Elodie Hélène Cadot2

  • 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Drug discovery today
|October 18, 2023
PubMed
概括

用非共价抑制剂向凯尔奇类ECH相关蛋白1 (Keap1) 为氧化应激和炎症提供了一个有前途的治疗策略. 这些化合物调节核因素红色素2相关因子2 (Nrf2) 途径,为现有的共价药物提供了替代品.

更多相关视频

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

843
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

相关实验视频

Last Updated: Jul 13, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

843
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

科学领域:

  • 药理学和药物发现
  • 分子生物学分子生物学
  • 生物化学 生化学

背景情况:

  • 凯尔奇类ECH相关蛋白1 (Keap1) 是一种关键的药物标,用于具有氧化应激和炎症特征的疾病.
  • 目前的治疗策略包括三种已批准的共价Keap1结合药物.
  • 针对Keap1-Nrf2相互作用的非共价抑制剂提供了具有明显药理特征的可行的替代方案.

研究的目的:

  • 探索利用共价抑制剂和非共价抑制剂针对Keap1的机会和挑战.
  • 提供现有的非共价Keap1-Nrf2抑制剂的综合性审查.
  • 通过检查它们的药理作用来评估非共价抑制剂的治疗潜力.

主要方法:

  • 对现有的共价和非共价Keap1抑制剂进行文献综述和分析.
  • 对不同类型的抑制剂的非标特征和药学动力学影响进行比较评估.
  • 专注于非共价Keap1-Nrf2抑制剂的药理机制和治疗影响.

主要成果:

  • 协同抑制剂和非协同抑制剂都能阻止核因子红色素2相关因子2 (Nrf2) 的降解,从而诱导抗氧化和抗炎反应.
  • 在共价和非共价药物类别之间的非标特征和精确的药学动力学结果中存在显著差异.
  • 非共价抑制剂显示出相当大的治疗潜力,需要进一步研究.

结论:

  • 非共价Keap1-Nrf2抑制剂提供了一个有前途的治疗途径,与共价药物相比具有明显的优势.
  • 了解细微的药理学效应和非标特征对于优化非共价抑制剂开发至关重要.
  • 对非共价抑制剂的进一步研究是必不可少的,以充分实现它们在治疗与氧化应激和炎症有关的疾病中的治疗潜力.